mRNA-1273新冠疫苗盲法阶段完成时的效力
这项3期观察者盲法安慰剂对照试验在美国99个中心入组了30415名新冠高危志愿者,按1:1随机接种两剂mRNA-1273(100 μg)或安慰剂,间隔28天。盲法阶段中位随访5.3个月,预防新冠疾病效力为93.2%(95%CI 91.0-94.8),预防重症效力为98.2%(95%CI 92.8-99.6),预防无症状感染效力为63.0%(95%CI 56.6-68.5),未发现安全性问题。
要点
- mRNA-1273两剂100 μg间隔28天,预防新冠疾病效力93.2%。
- 预防重症效力98.2%,预防无症状感染效力63.0%。
- 效力在不同种族、年龄和基础疾病人群中一致。
核心结论
- mRNA-1273疫苗在超过5个月时持续有效预防新冠疾病和重症,安全性可接受,并观察到对无症状感染的保护。
研究设计与样本
- 3期观察者盲法安慰剂对照试验,在美国99个中心入组30415名新冠高危志愿者。
- 参与者按1:1随机接受两剂mRNA-1273(100 μg)或安慰剂肌注,间隔28天。
- 主要终点为未既往感染SARS-CoV-2者第二剂后至少14天起病的新冠疾病预防,数据截止2021年3月26日。
主要发现
- 预防新冠疾病效力93.2%(95%CI 91.0-94.8),mRNA-1273组55例确诊(9.6/1000人年,95%CI 7.2-12.5),安慰剂组744例(136.6/1000人年,95%CI 127.0-146.8)。
- 预防重症效力98.2%(95%CI 92.8-99.6),mRNA-1273组2例,安慰剂组106例。
- 第二剂后14天起预防无症状感染效力63.0%(95%CI 56.6-68.5),mRNA-1273组214例,安慰剂组498例。
- 效力在不同 ethnic and racial groups、年龄组及有合并症参与者中一致。
- 未发现安全性问题。
关键数值与推荐
- mRNA-1273组100 μg两剂间隔28天。
- 疫苗效力定义基于第二剂后至少14天起病的新冠疾病。
- 盲法阶段中位随访5.3个月。
临床怎么用
- 支持mRNA-1273用于新冠高危人群预防疾病和重症。
- 对无症状感染有部分保护,但效力低于有症状疾病预防。
局限性
- 盲法阶段中位随访5.3个月,长期数据待报告。
- 数据截止2021年3月26日。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: At interim analysis in a phase 3, observer-blinded, placebo-controlled clinical trial, the mRNA-1273 vaccine showed 94.1% efficacy in preventing coronavirus disease 2019 (Covid-19). After emergency use of the vaccine was authorized, the protocol was amended to include an open-label phase. Final analyses of efficacy and safety data from the blinded phase of the trial are reported. METHODS: We enrolled volunteers who were at high risk for Covid-19 or its complications; participants were randomly assigned in a 1:1 ratio to receive two intramuscular injections of mRNA-1273 (100 μg) or placebo, 28 days apart, at 99 centers across the United States. The primary end point was prevention of Covid-19 illness with onset at least 14 days after the second injection in participants who had not previously been infected with the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The data cutoff date was March 26, 2021. RESULTS: The trial enrolled 30,415 participants; 15,209 were assigned to receive the mRNA-1273 vaccine, and 15,206 to receive placebo. More than 96% of participants received both injections, 2.3% had evidence of SARS-CoV-2 infection at baseline, and the median follow-up was 5.3 months in the blinded phase. Vaccine efficacy in preventing Covid-19 illness was 93.2% (95% confidence interval [CI], 91.0 to 94.8), with 55 confirmed cases in the mRNA-1273 group (9.6 per 1000 person-years; 95% CI, 7.2 to 12.5) and 744 in the placebo group (136.6 per 1000 person-years; 95% CI, 127.0 to 146.8). The efficacy in preventing severe disease was 98.2% (95% CI, 92.8 to 99.6), with 2 cases in the mRNA-1273 group and 106 in the placebo group, and the efficacy in preventing asymptomatic infection starting 14 days after the second injection was 63.0% (95% CI, 56.6 to 68.5), with 214 cases in the mRNA-1273 group and 498 in the placebo group. Vaccine efficacy was consistent across ethnic and racial groups, age groups, and participants with coexisting conditions. No safety concerns were identified. CONCLUSIONS: The mRNA-1273 vaccine continued to be efficacious in preventing Covid-19 illness and severe disease at more than 5 months, with an acceptable safety profile, and protection against asymptomatic infection was observed. (Funded by the Biomedical Advanced Research and Development Authority and the National Institute of Allergy and Infectious Diseases; COVE ClinicalTrials.gov number, NCT04470427.).
引用
- El Sahly HM, Baden LR, Essink B, et al. Efficacy of the mRNA-1273 SARS-CoV-2 Vaccine at Completion of Blinded Phase. N Engl J Med. 2021. PMID: 34551225. doi:10.1056/NEJMoa2113017
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。